Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Febrile neutropenia: practical aspects]

P Harten1, B Seyfarth, N Schmitz

  • 1II. Medizinische Klinik und Poliklinik, Christian-Albrechts-Universität Kiel. P.Harten@2med.uni-kiel

Medizinische Klinik (Munich, Germany : 1983)
|December 16, 1998
PubMed
Summary

Managing febrile neutropenia requires strategic antibiotic use to achieve high response rates. Further research is needed to explore outpatient treatment options for select patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evidence of Spin-Interference Effects in Exclusive J/ψ→e^{+}e^{-} Photoproduction in Ultraperipheral Heavy-Ion Collisions.

Physical review letters·2026
Same author

First Observation of Deuteron-Λ Correlations at RHIC.

Physical review letters·2026
Same author

Observation of Charmonium Sequential Suppression in Heavy-Ion Collisions at the Relativistic Heavy Ion Collider.

Physical review letters·2026
Same author

Energy Independence of the Collins Asymmetry in p^{↑}p Collisions.

Physical review letters·2026
Same author

Precision Measurement of Net-Proton-Number Fluctuations in Au+Au Collisions at RHIC.

Physical review letters·2025
Same author

Measurement of Two-Point Energy Correlators within Jets in p+p Collisions at sqrt[s]=200  GeV.

Physical review letters·2025

Area of Science:

  • Infectious Diseases
  • Hematology
  • Pharmacoeconomics

Context:

  • Febrile neutropenia poses a significant mortality risk in patients undergoing chemotherapy or with other conditions causing low neutrophil counts.
  • Effective management is crucial to reduce prolonged hospital stays and high healthcare costs associated with infections in this vulnerable population.

Purpose:

  • To review the practical and economic considerations for managing febrile neutropenia.
  • To outline current therapeutic strategies and their efficacies.

Summary:

  • First-line treatments include aminoglycosides with ureidopenicillin or third-generation cephalosporins; double beta-lactam combinations offer similar efficacy with reduced toxicity but higher cost.
  • Monotherapy with carbapenems, ceftazidime, or cefepime shows comparable effectiveness.
  • For persistent infections or lung infiltrates, escalating therapy with carbapenems, glycopeptides, and antifungals is recommended. Hematopoietic growth factors are reserved for high-risk cases.

Impact:

  • The discussed therapeutic approach achieves response rates exceeding 90%.
  • Consistent, stepwise antibiotic escalation is key to successful outcomes.
  • Further investigation is warranted to determine the feasibility and safety of outpatient management for selected patients with febrile neutropenia.

Related Experiment Videos